Featured

Schrödinger Reports Encouraging Phase 1 Data for SGR-1505 in Relapsed/Refractory B-cell Malignancies

June 12, 2025

Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...

Clinical trial Updates

Schrödinger Reports Encouraging Phase 1 Data for SGR-1505 in Relapsed/Refractory B-cell Malignancies

Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...

BIMZELX® (bimekizumab) Shows Lasting Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis After Three Years

UCB announced three-year data from Phase 3 trials and open-label extensions showing sustained efficacy of BIMZELX® (bimekizumab) in treating adults wi...

Vaxart's Second-Generation Norovirus Vaccine Shows Significantly Increased Antibody Responses in Phase 1 Trial

Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine. The trial...

MolecuLight Imaging Improves Deep Sternal Wound Infection Outcomes and Reduces Costs in Taiwan Study

A clinical study published in the Journal of Wound Care demonstrates that MolecuLight's i:X® device significantly improves outcomes for deep sternal w...

Kazia Therapeutics Announces Preclinical Data on Paxalisib for Triple-Negative Breast Cancer

Kazia Therapeutics announced the publication of preclinical research in Molecular Cancer Therapeutics demonstrating paxalisib's potential to overcome ...

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid Tumors

BioInvent International AB announced positive Phase 1 data for its drug candidate BI-1206, used in combination with Merck's KEYTRUDA (pembrolizumab), ...

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Travere Therapeutics announced it will present new data on FILSPARI (sparsentan) at the International Podocyte Conference. Data from the Phase 2 SPAR...

Harmony Biosciences Presents Preclinical Data for BP1.15205, a Potential Best-in-Class OX2R Agonist for Narcolepsy

Harmony Biosciences announced positive preclinical data for BP1.15205, a novel orexin 2 receptor (OX2R) agonist, demonstrating significant wake-promot...

Masimo SedLine® Improves Pediatric Anesthesia Outcomes

A randomized clinical trial published in JAMA Pediatrics demonstrates that EEG-guided anesthesia using Masimo SedLine® Brain Function Monitoring signi...

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up Results

Envoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...

Novo Nordisk to Present New Data on Semaglutide, CagriSema, and Amycretin at ADA 2025

Novo Nordisk announced it will present new data at the American Diabetes Association (ADA) 85th Scientific Sessions in June 2025. This includes Phase...

Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B Trial

Vergent Bioscience announced positive Phase 2B VISUALIZE trial results for abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent. The tr...

Hologic Presents New Data on Breast Cancer Index® Test at ASCO 2025

Hologic announced new data on the Breast Cancer Index® (BCI®) test, to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Me...

Servier to Present Updates on IDH-Mutated Cancer Research at ASCO 2025

Servier announced it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Presenta...

Tiziana Life Sciences Highlights Intranasal Foralumab for Moderate Alzheimer's Disease

Tiziana Life Sciences announced positive advancements in moderate Alzheimer's disease treatment using intranasal foralumab, a fully human anti-CD3 mon...

Positive Updated Results for Avutometinib Plus Defactinib in Frontline Metastatic Pancreatic Cancer

Verastem Oncology announced positive updated results from the RAMP 205 Phase 1/2 trial evaluating the combination of avutometinib and defactinib with ...

CytoSorbents Therapy Reduces Bleeding in Urgent CABG Patients on Ticagrelor

CytoSorbents Corporation announced results from a real-world data analysis presented at EuroPCR 2025, showing that its CytoSorbents therapy significan...

EMD Serono Presents Oncology Data at ASCO 2025

EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights in...

Daiichi Sankyo Presents Practice-Changing ENHERTU Data at ASCO 2025

Daiichi Sankyo announced positive late-breaking data from two phase 3 trials, DESTINY-Breast09 and DESTINY-Gastric04, highlighting ENHERTU (trastuzuma...

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy

ImCheck Therapeutics announced positive interim data from its Phase I/II EVICTION study evaluating ICT01, a γ9δ2 T-cell activator, in combination with...

Alligator Bioscience Presents Positive Biomarker Data for Mitazalimab in Pancreatic Cancer at ASCO 2025

Alligator Bioscience announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 ASCO Annual Meeting. OPTIMIZE-1 is a ...

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment Outcomes

MiraDx announced two studies to be presented at ASCO 2025, showcasing their mirSNP platform's ability to predict treatment-related toxicity and respon...

HUTCHMED to Present Clinical Data at 2025 ASCO Annual Meeting

HUTCHMED announced that new data from several clinical studies of its compounds, including savolitinib, ranosidenib, fruquintinib, and surufatinib, wi...

SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025

SystImmune, Inc. announced that data from clinical trials evaluating izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjuga...

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...

Biodesix to Present VeriStrat® Test Data at ASCO 2025

Biodesix announced new data from the INSIGHT study (NCT03289780) on the VeriStrat® Host Immune Classifier (HIC) test, to be presented at the 2025 ASCO...

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metasta...

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...

Linvoseltamab Combination Therapy Shows Promising Results in Multiple Myeloma

Regeneron Pharmaceuticals announced positive initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with carfilzom...

Legend Biotech Presents New Data on CARVYKTI® and Pipeline Candidates at ASCO, EHA, and ASGCT

Legend Biotech announced new data on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for multiple myeloma, to be presented at ASCO and EHA. Lo...

Genmab to Present Late-Stage Oncology Data at ASCO 2025

Genmab announced it will present new data at the 2025 ASCO Annual Meeting, focusing on its late-stage oncology portfolio. Key highlights include the ...

Bicycle Therapeutics Announces Positive Clinical Trial Results for Zelenectide Pevedotin at ASCO 2025

Bicycle Therapeutics announced the presentation of two abstracts at the 2025 ASCO Annual Meeting, showcasing preliminary results from their Phase 1/2 ...

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025

Avidicure announced it will present preclinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights AVC...

Columvi Extends Overall Survival in Relapsed/Refractory DLBCL Patients: Two-Year Follow-up Data

Roche announced two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival (OS) for patients with relapse...

Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual Meeting

Autobahn Therapeutics announced positive Phase 1 clinical trial results for ABX-002, a novel thyroid hormone beta receptor (TRβ) selective agonist, at...

Exact Sciences Highlights Cancer Detection Innovations at ASCO 2025

Exact Sciences announced the presentation of ten abstracts at the 2025 ASCO Annual Meeting, showcasing new data on its Oncodetect MRD test, multi-canc...

Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver Fibrosis

Gyre Therapeutics announced positive Phase 3 results for Hydronidone (F351) in treating liver fibrosis associated with chronic hepatitis B (CHB) in Ch...

Guardant Health to Present Liquid Biopsy Data at ASCO 2025

Guardant Health announced that it and its collaborators will present data from over 19 studies at the 2025 ASCO Annual Meeting. These studies highlig...

Kelun-Biotech Presents Positive Clinical Trial Data at ASCO 2025

Kelun-Biotech announced the publication of six abstracts from its clinical studies at the 2025 ASCO Annual Meeting. The abstracts highlight data on t...

ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025

ImPact Biotech announced that it will present interim data from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with low-grade upper tract...

Lilly Announces ASCO 2025 Presentations on Oncology Pipeline

Eli Lilly and Company announced that data from several investigational oncology therapies will be presented at the 2025 American Society of Clinical O...

Astria Therapeutics to Present Navenibart Data at C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics announced that it will present safety and efficacy data from Phase 1a and 1b/2 clinical trials of navenibart, a monoclonal antibod...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim announced that it will present new clinical data from two early-stage trials investigating SIRPα inhibitors at the 2025 ASCO Annu...

Petosemtamab Plus Pembrolizumab Shows Strong Efficacy in Head and Neck Cancer

Merus N.V. announced positive interim data from a Phase 2 trial of petosemtamab in combination with pembrolizumab for first-line treatment of PD-L1+ r...

XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

Five-year follow-up data from the Phase 3 ARCHES trial (NCT02677896) demonstrates that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) s...

Rakuten Medical Announces Phase 3 Trial Progress for ASP-1929 Photoimmunotherapy at ASCO 2025

Rakuten Medical announced that it will present a Trial in Progress poster at the 2025 ASCO Annual Meeting, showcasing its global Phase 3 clinical tria...

Positive Phase II Results for CARsgen's Satri-cel in Advanced Gastric Cancer

CARsgen Therapeutics announced positive results from a Phase II clinical trial (CT041-ST-01, NCT04581473) of satricabtagene autoleucel (satri-cel), a ...

Vistagen to Present Research on Itruvone and Fasedienol at ASCP Conference

Vistagen, a clinical-stage biopharmaceutical company, announced it will present at the 2025 American Society of Clinical Psychopharmacology (ASCP) Con...

Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC

Mythic Therapeutics announced positive efficacy data from the Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in ...

Pfizer to Present Phase 1 Data on MesoC2 ADC at ASCO 2025

Nona Biosciences announced that its collaborator, Pfizer, will present the Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-c...

Bristol Myers Squibb to Present Oncology Data at ASCO 2025

Bristol Myers Squibb announced the presentation of data from over 80 studies at the 2025 ASCO Annual Meeting. The data covers more than 20 cancer typ...

Updated Elacestrant Data Highlights Combinability in Metastatic Breast Cancer

Menarini Group presented updated data from the Phase 1b/2 ELEVATE study at ASCO 2025, showcasing the efficacy and safety of elacestrant (ORSERDU®) in ...

Taiho Oncology Presents Positive Data at ASCO 2025 Annual Meeting

Taiho Oncology announced new data to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include data on...

Merus' Bispecific Antibody Shows Promising Results in Head and Neck Cancer

Merus announced positive Phase II data for its bispecific antibody petosemtamab in combination with Keytruda (pembrolizumab) for first-line treatment ...

RWJBarnabas Health and Rutgers Cancer Institute to Present Cancer Research at ASCO 2025

RWJBarnabas Health and Rutgers Cancer Institute will present 45 abstracts and presentations at the 2025 ASCO Annual Meeting. Research highlights incl...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim will present data from two early-stage clinical trials investigating their SIRPα inhibitors, BI 765063 and BI 770371, at the 2025...

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation

Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...

Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin announced positive pivotal data for ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory (R/R) NPM1...

Exelixis Presents Encouraging Zanzalintinib Combination Therapy Results for Advanced Kidney Cancer at ASCO 2025

Exelixis announced positive results from the Phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with immune checkpoint inhibitors fo...

Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis

Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201, a sterically-optimized BCMA-targeted CAR-T cell th...

Improved Cardiac Surgery Outcomes with Active Chest Tube Clearance

ClearFlow, Inc. announced positive clinical trial results showing that its PleuraFlow Active Clearance Technology (ACT) System significantly improves ...

Avalyn Pharma Presents Positive Clinical Data for Inhaled Pulmonary Fibrosis Treatments at ATS 2025

Avalyn Pharma showcased positive clinical data for its lead programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), at the American Thorac...

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal Degeneration

Drs. Lanman and Ament performed the first known combined implantation of the MOTUS total joint replacement device and the TOPS™ System at adjacent lum...

ONWARD Medical Achieves Fifth Successful Brain-Computer Interface Implant

ONWARD Medical announced the successful implantation of its investigational ARC-BCI® Therapy in two additional individuals with spinal cord injury, br...

Zymeworks Presents Preclinical Data for ZW1528, a Novel Bispecific Antibody for Respiratory Inflammation

Zymeworks announced the presentation of preclinical data for ZW1528, a novel bispecific molecule targeting IL-4Rα and IL-33, at the American Thoracic ...

Be Biopharma Announces Preclinical Data for BE-102 in Hypophosphatasia

Be Biopharma presented preclinical data for BE-102, a B cell medicine, showing continuous secretion of active alkaline phosphatase (ALP) for up to six...

IMVARIA Presents Multi-Site Clinical Data on AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025

IMVARIA Inc. announced the presentation of multi-site clinical experience results with its FDA-authorized AI diagnostic service, Fibresolve, at the AT...

Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension

Tectonic Therapeutic announced positive complete results from Part A of its Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hyperte...

Innate Pharma's Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma announced that four abstracts featuring its clinical-stage drugs will be presented at the American Society of Clinical Oncology (ASCO) 2...

LIfT BioSciences Presents Preclinical Data on Immunomodulatory Alpha Neutrophils (IMANs) for Solid Tumors

LIfT BioSciences announced the presentation of preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) at the ISCT 2025 Annu...

Cantargia's CAN10 Shows Promise in Inhibiting Vascular Inflammation

Cantargia AB announced promising preclinical results for CAN10, an antibody targeting IL1RAP, in vascular inflammation models. The study, published i...

CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASH

CureGene Pharmaceuticals announced preclinical data for its investigational drug, CG-0416, a liver-targeted thyroid hormone receptor beta (THR-β) prod...

SELLAS Life Sciences Initiates Pediatric AML Patient Dosing in Phase 2 SLS009 Trial

SELLAS Life Sciences announced the first pediatric patient has been dosed in its ongoing Phase 2 trial of SLS009 (tambiciclib) for relapsed/refractory...

Abbott's FreeStyle Libre CGM Reduces Cardiovascular Hospitalizations in People with Diabetes

New data from Abbott's REFLECT real-world studies show that using FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a ...

Voyager Therapeutics Announces Publication Demonstrating Novel AAV Capsid for Blood-Brain Barrier Transport

Voyager Therapeutics announced the publication of data in Molecular Therapy demonstrating the ability of alkaline phosphatase (ALPL) to transport a no...

Novartis Presents Promising Oncology and Hematology Data at ASCO and EHA

Novartis announced the presentation of data from 60 abstracts at the 2025 ASCO Annual Meeting and EHA 2025 Congress. The data showcases the momentum ...

Soleno Therapeutics Announces Presentations on VYKAT XR for Prader-Willi Syndrome at PES 2025

Soleno Therapeutics announced poster presentations on its VYKAT XR (diazoxide choline) extended-release tablets at the Pediatric Endocrine Society (PE...

First Participant Dosed in ACT-EARLY: A Primary Prevention Study for Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma announced the first participant has been dosed in ACT-EARLY, the first-ever primary prevention study for transthyretin amyloid cardio...

Hemogenyx Pharmaceuticals Expands Pediatric R/R AML Trial for HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals plc announced a protocol amendment to include pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML) i...

Merck to Present Oncology Research at ASCO 2025

Merck announced that it will present new research on its oncology portfolio and pipeline at the 2025 ASCO Annual Meeting. Data will be showcased acro...

Zomedica Launches Equine Asthma Clinical Registry Using PulseVet Shock Wave Therapy

Zomedica Corp. announced the launch of the Equine Asthma Clinical Registry, a program utilizing PulseVet® shock wave therapy as a non-invasive, drug-f...

Indivior Advances Addex's GABAB PAM Program Through IND Enabling Studies

Indivior, partnering with Addex Therapeutics, successfully completed IND-enabling studies for a GABAB positive allosteric modulator (PAM) targeting su...

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic Dermatitis

AbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis. The da...

Applied Therapeutics to Present Updated Data on Govorestat at PNS 2025 Meeting

Applied Therapeutics will present 12-month clinical data and new 18- and 24-month topline data from the INSPIRE Phase 3 trial of govorestat (AT-007) f...

Aspen Neuroscience Announces Positive 6-Month Results for Parkinson's Disease Cell Therapy

Aspen Neuroscience announced positive 6-month results from the ASPIRO Phase 1/2a trial of ANPD001, a personalized cell therapy for Parkinson's disease...

ZIVO Bioscience Announces Positive Results in Avian Influenza Study

ZIVO Bioscience announced positive results from a University of Delaware study evaluating its algal-derived ingredients to mitigate avian influenza in...

Nadunolimab Plus Pembrolizumab Shows Potential in Solid Tumors

Cantargia announced the publication of clinical trial results in Investigational New Drugs, showing the potential of nadunolimab combined with pembrol...

Endogenex Presents Positive 48-Week REGENT-1 Clinical Trial Results for Type 2 Diabetes Treatment

Endogenex announced positive 48-week results from its REGENT-1 clinical study at Digestive Disease Week 2025. The study evaluated the safety and effic...

Darnatein to Present Advances in Regenerative Biologics at BMP Conference

Darnatein, a subsidiary of OSR Holdings, will present data at the 14th International Bone Morphogenetic Protein (BMP) Conference on May 3, 2025. Dr. ...

Nutshell Therapeutics Receives FDA Clearance for Phase 1 Trial of NTS071

Nutshell Therapeutics announced that the US FDA has cleared its Investigational New Drug (IND) application for NTS071, an oral, small molecule alloste...

JediCare Medical Announces Successful First-in-Human Study of Novel Pulmonary Nodule Removal Device

JediCare Medical, in collaboration with West China Hospital, successfully completed a first-in-human feasibility study of their Pulmonary Nodule Grabb...

OBI Pharma's OBI-902 IND Application Cleared for Phase 1/2 Trial in Advanced Solid Tumors

OBI Pharma announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OBI-902, a Trop-2...

Bolt Biotherapeutics Presents Preclinical Data on Next-Generation Boltbody™ ISACs

Bolt Biotherapeutics announced preclinical results for its next-generation Boltbody™ ISACs targeting CEA and PD-L1 at the AACR Annual Meeting 2025. T...

Microglia Replacement Shows Promise in Treating Leukodystrophies

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania have developed a novel approach to treating leukodystroph...

Genocury Biotech's In Vivo CD19 CAR-T Therapy Shows Promise in Relapsed/Refractory DLBCL

Genocury Biotech announced positive clinical trial results for its novel in vivo CD19 CAR-T therapy treating relapsed/refractory diffuse large B-cell ...

DecisionDx-Melanoma Test Outperforms Existing Methods in Identifying Low-Risk Melanoma Patients

A new study published in Cancer Diagnosis & Prognosis shows that Castle Biosciences' DecisionDx-Melanoma test surpasses both American Joint Committee ...

Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia

Neurocrine Biosciences has initiated a Phase 3 registrational program for NBI-1117568, an oral muscarinic M4 selective receptor agonist, as a potentia...

Home/KnloSights/clinical trial updates